AISHA SABIR: Open Payments
NPI 1609970631 · CONCORD, NH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$793 in 51 payments from 9 companies in 2025. Trend: 2023 $406 · 2024 $791 · 2025 $793
Food & beverage: $793
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 30 | $251 |
| Otsuka America Pharmaceutical, Inc. | 5 | $191 |
| Vanda Pharmaceuticals Inc. | 6 | $145 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $97 |
| ABBVIE INC. | 2 | $33 |
| Janssen Pharmaceuticals, Inc | 1 | $24 |
| Neurocrine BioSciences, Inc. | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
| Alkermes, Inc. | 1 | $16 |
Products named: UZEDY, FANAPT, ABILIFY MAINTENA, CAPLYTA, REXULTI, VRAYLAR, ABILIFY ASIMTUFII, INVEGA SUSTENNA.
Industry payments across NH — which companies pay providers there.
